Lung metastases are most common in clear cell renal cell carcinoma, whereas lymph node metastases and liver metastases occur most frequently in papillary and chromophobe RCC, respectively, investigators reported.
Previous findings from the TIVO-3 trial showed that tivozanib offered superior progression-free survival compared with sorafenib in patients with refractory metastatic renal cell carcinoma, but the latest analysis found no significant difference in overall survival.
After receiving intense hormone therapy prior to radical prostatectomy, one-fifth of men with high-risk localized prostate cancer had no tumor or residual tumor smaller than 5 mm following surgery, a study found.
Almost 40% of men with metastatic castration-resistant prostate cancer experience radiographic disease progression while on second-generation hormone therapy despite stable or declining PSA, a study found.
After a median time of 28.4 months, 40.6% of patients treated with pembrolizumab for high-risk nonmuscle-invasive bladder unresponsive to bacillus Calmette-Guérin (BCG) therapy had a complete response to the drug, and the median duration of response was 16.2 months.
Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
A study of patients undergoing radical prostatectomy found that those chronic kidney disease or end-stage renal disease have a higher risk of 30- and 90-day readmission and 1-year mortality.
Findings from a new study can help individualize prognoses for men with biochemical recurrence of prostate cancer after radical prostatectomy.
Decreased frequency of surveillance cystoscopies did not increase the risk of bladder cancer progression or death, study finds.
